Evoke Pharma, Inc. (EVOK) News
Filter EVOK News Items
EVOK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EVOK News Highlights
- EVOK's 30 day story count now stands at 4.
- Over the past 21 days, the trend for EVOK's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
Latest EVOK News From Around the Web
Below are the latest news stories about Evoke Pharma Inc that investors may wish to consider to help them evaluate EVOK as an investment opportunity.
Evoke Pharma and EVERSANA Announce Positive Findings from GIMOTI® Market Research StudyEvoke Pharma, Inc. Trend Across Waves for Proportion of Respondents Who Are Highly Familiar With GIMOTI (score of 4 or 5 out of 5) Health care practitioners’ perception of nasal route of administration similar to IV; 92% intend to prescribe GIMOTI Evoke attending American College of Gastroenterology (ACG) Annual Conference in Las Vegas, October 22-27, 2021 SOLANA BEACH, Calif. and CHICAGO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company foc |
Evoke Pharmas Commercial Partner EVERSANA, Receives PM360s Trailblazer Initiative Award for Innovation in Healthcare Marketing for GIMOTIAward for Spray Away Campaign seeking to drive patient and provider awareness for the novel nasal spray treatment of symptoms of Diabetic Gastroparesis |
Evoke Pharma’s Commercial Partner EVERSANA, Receives PM360’s Trailblazer Initiative Award for Innovation in Healthcare Marketing for GIMOTIAward for “Spray Away” Campaign seeking to drive patient and provider awareness for the novel nasal spray treatment of symptoms of Diabetic Gastroparesis SOLANA BEACH, Calif., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma® (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, a leading provider of global commercial services to the life sciences industry, today announced that PM360, a publication for marketing decision makers |
Evoke Pharma (NASDAQ:EVOK) Has Debt But No Earnings; Should You Worry?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says... |
Evoke Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment ConferenceSOLANA BEACH, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer R.Ph., President and Chief Executive Officer, and Matt DOnofrio, Chief Business Officer, will participate virtually in the H.C. Wainwright 23rd Annual Global Investment Conference taking place from September 13 15, 2021. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayGood morning, investor! |
24 Stocks Moving in Monday's Pre-Market SessionGainers Enlivex Therapeutics Ltd. (NASDAQ: ENLV) shares rose 26.6% to $12.87 in pre-market trading after the company disclosed that after reviewing its earlier-reported Phase II trial data, the Israeli Ministry of Health has authorized the initiation of a multi-center, placebo-controlled, randomized, blinded, Phase IIb clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients with acute respiratory distressed syndrome. Surgalign Holdings, Inc. (NASDAQ: SRGA) rose 22.1% to $1 |
Evoke Pharma Reports Second Quarter 2021 Financial ResultsApproximately 162% growth in product sales, 152% growth in prescriptions and 57% increase in new prescribers for Gimoti® Extends cash runway into third quarter of 2022 SOLANA BEACH, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the second quarter that ended June 30, 2021 which includes recent corporate developments. “Throu |
Evoke Pharma to Report Second Quarter 2021 Financial Results on August 12, 2021SOLANA BEACH, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that the Company is scheduled to release its second quarter 2021 financial results on Thursday, August 12, 2021, after the market closes. |
Evoke Pharma and EVERSANA Announce Support of The International Foundation for Gastrointestinal Disorders (IFFGD) August Gastroparesis Awareness MonthParticipating and Sponsorship in Upcoming Digestive Health Virtual Walk Participating and Sponsorship in Upcoming Digestive Health Virtual Walk |